Supporting Families of School-Aged Children With ADHD: A Dual-Generation Therapy Approach Through the BRIDGE Program
NCT07926776, Not applicable, Not yet recruiting, University of Manitoba
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Supporting Families of School-Aged Children With ADHD: A Dual-Generation Therapy Approach Through the BRIDGE Program | ClinicalTrials.gov |
| NCT number | NCT07926776 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 30 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | University of Manitoba | ClinicalTrials.gov |
| Conditions | ADHD, Maternal Mental Health, Dialectical Behavior Therapy, Parenting Intervention, Children | ClinicalTrials.gov |
| Interventions | BRIDGE-ADHD | ClinicalTrials.gov |
| First posted | 2026-11-09 | ClinicalTrials.gov |
| Last updated | 2026-11-09 | ClinicalTrials.gov |
Registered outcomes 28
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Changes in child mental health symptoms following BRIDGE-ADHD intervention | This measure will be administered at baseline, (week 0-1; noted as T0) and after 10 weeks of BRIDGE intervention, post-intervention which will occur between weeks 11-12 (noted as T1). | Changes in child mental health symptoms will be measured using the Child Behavior Checklist (CBCL) for ages 6 to 18. The CBCL is a 100-item parent-report questionnaire with a range of scores from 0 to 200, measuring child functioning across externalizing and internalizing symptoms. All raw scores are converted into T-scores across all domains tested to have a standardized outcome. Higher T-scores indicate greater symptom severity. We will use the CBCL to assess a) total behaviour problems, b) ADHD subscale scores, c) internalizing behaviours, and d) externalizing behaviours. These subscale scores will collectively be investigated as child mental health symptoms. | ClinicalTrials.gov |
| Primary | Changes in maternal depressive symptoms | This measure will be administered at baseline, which is considered week 0-1 (noted as T0) and after 10 weeks of BRIDGE intervention, post-intervention taking place at weeks 11-12 ( noted as T1). | Depressive symptoms will be measured using the Patient Health Questionnaire 9-Item (PHQ-9). The PHQ-9 is a 9-item self-report questionnaire with a range of scores from 0 to 27. Higher scores indicate greater symptom severity. | ClinicalTrials.gov |
| Primary | Maternal ratings of program acceptability | This measure will be administered after the 10 week of BRIDGE intervention, post-intervention (noted as T1) expected to take place sometime between weeks 11-12. | Maternal ratings of program acceptability will be collected using an open-ended program acceptability questionnaire developed by the research team. Participants will rate how important various components of the program were to them and will be asked to respond to open-ended questions regarding their experience in the program. | ClinicalTrials.gov |
| Primary | Recruitment Feasibility Metrics | These will be measured from beginning of the study recruitment till the end of the pilot trial. This time frame can be up to 1 year. | The feasibility of the BRIDGE-ADHD program will be evaluated using a range of implementation metrics. Recruitment feasibility will be assessed by examining eligibility rates, enrollment rates, and the time required to recruit the target sample. All of these measures will be presented in rates allowing for common measurement across domains. | ClinicalTrials.gov |
| Primary | Data Collection Feasibility | These will be measured from beginning of the study recruitment till the end of the pilot trial. This time frame can be up to 1 year. | The feasibility of the BRIDGE-ADHD program will be evaluated using a range of implementation metrics. Data collection feasibility will be determined by the proportion of participants completing baseline and post-intervention assessments, rates of missing data, and the time required to complete study measures. | ClinicalTrials.gov |
| Primary | Program Implementation Outcomes | These will be measured from beginning of the study recruitment till the end of the pilot trial. This time frame can be up to 1 year. | Program implementation outcomes, including session attendance, reasons for missed sessions or withdrawal, scheduling challenges, technological issues and facilitator reflections on program delivery | ClinicalTrials.gov |
| Primary | Program Retention Measure | These will be measured from beginning of the study recruitment till the end of the pilot trial. This time frame can be up to 1 year. | Retention and adherence will be measured by the proportion of participants who complete the program, attendance rates across the 10 sessions, and watching home videos, where applicable. | ClinicalTrials.gov |
| Secondary | Changes in parent ratings of child behaviours | This measure will be administered at baseline, (week 0-1; noted as T0) and after 10 weeks of BRIDGE intervention, post-intervention which will occur between weeks 11-12 (noted as T1). | Changes in parent ratings of child behaviours will be measured using the Behaviour Assessment System for Children - Third Edition (BASC-3). The BASC-3 is a parent-report questionnaire measuring externalizing and internalizing problems, attention problems, school problems, as well as adaptive strengths like social skills and study skills. All raw scores are converted into T-scores across all domains tested to have a standardized outcome. Higher T-scores on problem factors indicate more severe problems. Higher T-scores on strengths indicate more of those strengths. We will be specifically looking at broader subscale scores to identify if there has been any change in child behaviours. | ClinicalTrials.gov |
| Secondary | Changes in Parenting stress | This measure will be administered at baseline (week 0-1; noted as T0) and after 10 weeks of BRIDGE intervention, post-intervention, which will occur between weeks 11-12 (noted as T1). | Parenting stress will be measured using the Parenting Stress Index Short Form (PSI-SF). The PSI-SF is a self-report questionnaire requiring respondents to answer questions regarding their overall experience of parenting stress using a 5-point Likert with a range of scores range from 36 to 180. All raw scores are converted into T-scores across all domains tested to have a standardized outcome. Higher T-scores indicate higher levels of parenting stress. Changes in total parenting stress score will be measured. | ClinicalTrials.gov |
| Secondary | Changes in difficulties with maternal emotion regulation | This measure will be administered at baseline (week 0-1; noted as T0) and after 10 weeks of BRIDGE intervention, post-intervention, which will occur between weeks 11-12 (noted as T1). | Changes in difficulties with emotion regulation will be measured using the Difficulties in Emotion Regulation 36-Item Scale (DERS-36). The DERS-36 is a self-report questionnaire assessing emotion dysregulation across 6 dimensions, including nonacceptance of emotions, difficulties with goal-directed behaviour, impulse control, lack of emotional awareness, limited access to regulation strategies, and lack of emotional clarity. Respondents rate often each statement describes them on a 5-point Likert scale with higher scores indicating greater difficulties. All raw scores are converted into T-scores across all domains tested to have a standardized outcome. Total scores range from 36 to 180 with higher score indicating greater overall difficulties with emotion regulation. Changes in total emotion regulation T-score will be measured. | ClinicalTrials.gov |
| Secondary | Changes in maternal feelings of anger | This measure will be administered at baseline (week 0-1; noted as T0) and after 10 weeks of BRIDGE intervention, post-intervention, which will occur between weeks 11-12 (noted as T1). | Changes in anger will be measured using the Patient-Reported Outcomes Measurement Information System (PROMIS) Anger subscale. The PROMIS Anger subscale contains 5 items with a range of scores from 5 to 25. Higher scores indicate higher levels of anger. | ClinicalTrials.gov |
| Secondary | Changes in maternal sleep problems | This measure will be administered at baseline (week 0-1; noted as T0) and after 10 weeks of BRIDGE intervention, post-intervention, which will occur between weeks 11-12 (noted as T1). | Changes in maternal sleep disturbances will be measured using the Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance subscale short form. The subscale contains 8 items with a range of scores from 8 to 40. Higher scores indicate greater sleep disturbance severity. | ClinicalTrials.gov |
| Secondary | Changes in children's sleep habits | This measure will be administered at baseline (week 0-1; noted as T0) and after 10 weeks of BRIDGE intervention, post-intervention, which will occur between weeks 11-12 (noted as T1). | Changes in children's sleep habits will be measured using the Children's Sleep Habits Questionnaire (CSHQ). The CSHQ is a 45-item parent-report questionnaire assessing common sleep problems in children aged 4 to 12, including bedtime resistance and night waking. Higher scores indicate more severe sleep problems with scores above 41 suggesting clinical concerns. | ClinicalTrials.gov |
| Secondary | Changes in maternal anxiety symptoms | This measure will be administered at baseline (week 0-1; noted as T0) and after 10 weeks of BRIDGE intervention, post-intervention, which will occur between weeks 11-12 (noted as T1). | Anxiety symptoms will be measured using the Generalized Anxiety Disorder 7-Item Scale (GAD-7). The GAD-7 contains 7 items with a range of scores from 0 to 21. Higher scores indicate higher levels of anxiety symptoms. | ClinicalTrials.gov |
| Secondary | Changes in maternal Attention and Hyperactivity symptoms | This measure will be administered at baseline (week 0-1; noted as T0) and after 10 weeks of BRIDGE intervention, post-intervention, which will occur between weeks 11-12 (noted as T1). | Changes in maternal ADHD symptoms will be measured using the Adult ADHD Self-Report Scale (ASRS). The ASRS is an 18-item questionnaire screening for ADHD symptoms in adults based on DSM criteria. Part A of the scale contains 6 items screening for the most predictive symptoms and Part B collects additional details. Total scores range from 0 to 72 with higher scores indicating greater frequency and severity of ADHD symptoms. All raw scores are converted into T-scores across all domains tested to have a standardized outcome. | ClinicalTrials.gov |
| Secondary | Measure of Child health | This measure will be administered at baseline (noted as T0), expected to occur sometime between weeks 0-1. | Child health will be assessed using a parent-report questionnaire developed by the research team. Parents will be asked to respond to questions about their child's physical and mental health from birth to the present. | ClinicalTrials.gov |
| Secondary | Changes in harsh parenting | This measure will be administered at baseline (week 0-1; noted as T0) and after 10 weeks of BRIDGE intervention, post-intervention, which will occur between weeks 11-12 (noted as T1). | Changes in harsh parenting will be measured using the Behaviour Assessment System for Children - Third Edition (BASC-3) Parenting Relationship Questionnaire. The BASC-3 is an 87-item parent-report questionnaire for children aged 2 to 18 years with 7 parenting behaviour subscales, including communication and involvement. Higher scores indicate more of the relevant subscale. Specifically, change in harsh parenting will be measured. All raw scores are converted into T-scores across all domains tested to have standardized outcomes. | ClinicalTrials.gov |
| Other | Changes in parent report measures of child executive function skills | This measure will be administered at baseline (week 0-1; noted as T0) and after 10 weeks of BRIDGE intervention, post-intervention, which will occur between weeks 11-12 (noted as T1). | Changes in child executive function skills will be measured using the Behavior Rating Inventory of Executive Function - Second Edition (BRIEF-2). The BRIEF-2 is a 63-item parent-report questionnaire with 9 subscales, including inhibition, working memory, emotion control, and other clinically relevant subscales. Higher scores on each subscale indicate more of the relevant executive function skill. All raw scores are converted into T-scores across all domains tested to have standardized outcomes. | ClinicalTrials.gov |
| Other | Changes in academic achievement | This measure will be administered at baseline (week 0-1; noted as T0) and after 10 weeks of BRIDGE intervention, post-intervention, which will occur between weeks 11-12 (noted as T1). | Changes in academic achievement will be measured using the Weschler Individual Achievement Test - Fourth Edition (WIAT-4). The WIAT-4 is an individually administered assessment for ages 4 to 50 measuring 4 key areas of academic achievement, including mathematics, reading, written expression, and oral language. Each of these areas contain several relevant subtests. Raw scores on the WIAT-4 are converted into both percentile ranks and composite subtest scores. | ClinicalTrials.gov |
| Other | Changes in knowledge, pattern recognition, and problem solving | This measure will be administered at baseline (week 0-1; noted as T0) and after 10 weeks of BRIDGE intervention, post-intervention, which will occur between weeks 11-12 (noted as T1). | Changes in knowledge, pattern recognition, and problem solving will be measured using the Weschler Abbreviated Scale of Intelligence - Second Edition (WASI-II). The WASI-II is a standardized intelligence test for ages 6 to 90 with verbal and nonverbal subtests assessing various aspects of overall cognitive ability. All raw scores are converted into T-scores across all domains tested to have a standardized outcome. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 6
The papers the trial lists on ClinicalTrials.gov.
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 1
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Continuous Performance Test | Other outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)